bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cross‐Cultural Adaptation and Content Validation of the Yonsei Lifestyle Profile for Older Adults in the United States
Authors: Jin Yeonju , Lim Young‐Myoung , Hong Ickpyo 
Published: December 2024

ABSTRACTRationaleAs the global population ages, there is a growing need for tools to assess lifestyle factors that impact the health and quality of life of older adults. The Yonsei Lifestyle Profile (YLP), originally developed in South Korea, is a comprehensive tool for evaluating key lifestyle domains. However, cultural and linguistic differences between countries necessitate the adaptation of such tools for use in diverse populations. This study addresses the gap by developing an English version of the YLP (YLP‐E) for older adults in the United States.Aims and ObjectivesAs the global population continues to age, maintaining and improving the health and quality of life of older adults has become increasingly important. This study aimed to develop a YLP‐E, a cross‐cultural adaptation of the Korean version of the YLP, that can be used for older American adults.MethodThe Delphi method was used to consult expert panels regarding the cultural and linguistic appropriateness of the translation. The translation process involved a two‐way translation–back‐translation procedure and iterative revisions based on expert feedback.Results and ConclusionsThe final YLP‐E tool, which incorporated feedback on linguistic and cultural adequacy, consisted of 3 lifestyle domains (physical activity, activity participation and nutrition) with 62 items. The second round improved the content validity, with the linguistic content validity ratio (CVR) and cultural CVR reaching 0.86 and 0.94, respectively. The YLP‐E is a valuable tool for comprehensively assessing and monitoring the lifestyle of older American adults and holds promise for further refinement and validation across diverse demographic settings. Future research needs to focus on utilizing the YLP‐E to develop personalized interventions aimed at improving the health and quality of life of older adults and evaluating the tool's efficacy in promoting healthy aging.
Mass spectrometry identifies tau C‐terminal phosphorylation cluster during neuronal hyperexcitation
Authors: Schneeweis Amanda , Hillyer Dawson , Lama Tsering , Kim Daeun , Palka Charles , Djemil Sarra , Abdel‐Ghani Mai , Mandella Kelly , Zhu William , Alvarez Nicole , Stefansson Lara , Yasuda Robert , Ma Junfeng , Pak Daniel T.S. 
Published: December 2024

AbstractTau is a microtubule‐associated protein implicated in Alzheimer's disease (AD) and other neurodegenerative disorders termed tauopathies. Pathological, aggregated forms of tau form neurofibrillary tangles (NFTs), impairing its ability to stabilize microtubules and promoting neurotoxicity. Indeed, NFTs correlate with neuronal loss and cognitive impairment. Hyperphosphorylation of tau is seen in all tauopathies and mirrors disease progression, suggesting an essential role in pathogenesis. However, hyperphosphorylation remains a generic and ill‐defined term, obscuring the functional importance of specific sites in different physiological or pathological settings. Here, we focused on global mapping of tau phosphorylation specifically during conditions of neuronal hyperexcitation. Hyperexcitation is a property of AD and other tauopathies linked to human cognitive deficits and increased risk of developing seizures and epilepsy. Moreover, hyperexcitation promotes extracellular secretion and trans‐synaptic propagation of tau. Using unbiased mass spectrometry, we identified a novel phosphorylation signature in the C‐terminal domain of tau detectable only during neuronal hyperactivity in primary cultured rat hippocampal neurons. These sites influenced tau localization to dendrites as well as the size of excitatory postsynaptic sites. These results demonstrate novel physiological tau functions at synapses and the utility of comprehensive analysis of tau phosphorylation during specific signaling contexts.
image
Digital Technologies Enabling Component Reuse in Circular Value Chains: Using Digital Twin, Internet of Things and Robots in Construction and Manufacturing Sectors
Authors: Thakuri Prabhat Kiran , Alkki Lauri , Aarikka‐Stenroos Leena 
Published: December 2024

ABSTRACTThe reuse of components is a highly impactful way to implement the circular economy (CE) and limit negative environmental externalities in material‐intensive industries, such as construction and manufacturing. Although research integrating digitalisation and the CE has proposed a wide range of digital technologies to facilitate component reuse, these studies have limited their focus to single technologies and are centred on single firms, explaining how a single digital technology can support a single value chain actor to implement a specific circular solution. Consequently, we lack a comprehensive understanding of how digital technologies can enable the implementation of diverse component reuse practices—from design and disassembly to reassembly—undertaken by multiple actors in circular value chains. Against this backdrop, we conducted a qualitative multiple‐case study of how three digital technologies—addressing data‐driven modelling and analytics (Digital Twin), data collection and monitoring (Internet of Things [IoT]) and data‐informed automatisation (robots)—advance component reuse practices in construction and manufacturing value chains. Data were gathered from case companies through interviews, over 3 years of ethnographic observation supplemented with document analysis, and secondary sources. Three key results emerge from our study: first, these digital technologies offer eight enabling functions and thereby three fundamental instrumentalities for value chain actors to implement component reuse practices: knowledge optimisation, planning optimisation and improved operationalisation. Second, they offer five categories of business‐ and management‐related benefits, namely, circular systems design for reuse, improved physical processes, enhanced management of circular value chains, economic value optimisation and innovation and development. Third, benefits are realised at three levels within value chains, that is, individual actors, partnerships and entire value chains, allowing us to identify diversified scopes of benefits. Our findings are synthesised into a conceptual framework explaining in relative detail how digital technologies enable component reuse within circular value chains. This study contributes to the digitalisation and CE research and provides practical insights for both sectoral value chains and individual value chain actors on how digitalisation can maximise the effectiveness of component reuse to advance the CE transition.
Plasma transfusion in the intensive care unit
Authors: van Haeren Maite M. T. , Raasveld Senta Jorinde , de Bruin Sanne , Reuland Merijn C. , van den Oord Claudia , Schenk Jimmy , Aubron Cécile , Bakker Jan , Cecconi Maurizio , Feldheiser Aarne , de Grooth Harm‐Jan , Meier Jens , Scheeren Thomas W. L. , McQuilten Zoe , Flint Andrew , Hamid Tarikul , Piagnerelli Michaël , Mahečić Tina Tomić , Benes Jan , Russell Lene , Aguirre‐Bermeo Hernan , Triantafyllopoulou Konstantina , Chantziara Vasiliki , Gurjar Mohan , Myatra Sheila Nainan , Pota Vincenzo , Elhadi Muhammed , Gawda Ryszard , Mourisco Mafalda , Lance Marcus , Neskovic Vojislava , Podbregar Matej , Llau Juan V. , Quintana‐Diaz Manual , Cronhjort Maria , Pfortmueller Carmen A. , Yapici Nihan , Nielsen Nathan D. , Shah Akshay , Vlaar Alexander P. J. , Müller Marcella C. A. ,   the InPUT Study Group
Published: December 2024

AbstractBackgroundCurrent guidelines discourage prophylactic plasma use in non‐bleeding patients. This study assesses global plasma transfusion practices in the intensive care unit (ICU) and their alignment with current guidelines.Study Design and MethodsThis was a sub‐study of an international, prospective, observational cohort. Primary outcomes were in‐ICU occurrence rate of plasma transfusion, proportion of plasma events of total blood products events, and number of plasma units per event. Secondary outcomes included transfusion indications, INR/PT, and proportion of events for non‐bleeding indications.ResultsOf 3643 patients included, 356 patients (10%) experienced 547 plasma transfusion events, accounting for 18% of total transfusion events. A median of 2 (IQR 1, 2) units was given per event excluding massive transfusion protocol (MTP) and 3 (IQR 2, 6) when MTP was activated. MTP accounted for 39 (7%) of events. Indications of non‐MTP events included active bleeding (54%), prophylactic (25%), and pre‐procedure (12%). Target INR/PT was stated for 43% of transfusion events; pre‐transfusion INR/PT or visco‐elastic hemostatic assays (VHA) were reported for 73%. Thirty‐seven percent of events were administered for non‐bleeding indications, 54% with a pre‐transfusion INR < 3.0 and 30% with an INR < 1.5.DiscussionPlasma transfusions occurred in 10% of ICU patients. Over a third were given for non‐bleeding indications and might have been avoidable. Target INR/PT was not stated in more than half of transfusions, and pre‐transfusion INR/PT or VHA was not reported for 27%. Further research and education is needed to optimize guideline implementation and to identify appropriate indications for plasma transfusion.
Quantifying the impact of a novel virus on the economic value of pathogen reduction technology for platelets
Authors: Irving Adam , Simmonds Peter , Irving William , Thomas Stephen , Neuberger James 
Published: December 2024

AbstractBackgroundPathogen reduction technology (PRT) is an intervention designed to proactively reduce the amount of known and unknown pathogens in donated blood. As current screening for known pathogens is highly effective, some previous evaluations have found that the value of PRT largely hinges on a previously unknown pathogen, most likely a novel virus, emerging and entering the blood supply. In such situations, the risk of emergence can and should be modeled and presented transparently in the cost‐effectiveness results for deliberation by decision‐makers.Study Design and MethodsWe built a Markov cohort model assessing the economic value of introducing PRT for platelets in the United Kingdom. Input data were obtained from the existing PRT literature, national sources, or by conservative assumption. The primary objective of the study was to demonstrate methods for modeling and presenting the risk of emergence of a novel virus, using alternative time‐to‐emergence scenarios in the probabilistic sensitivity analysis.ResultsAs expected, PRT will be more cost‐effective the sooner the novel virus emerges after the introduction of PRT. In the base‐case cost scenario, the deterministic ICER was £270 K/QALY gained if the virus emerged immediately and rose to £3.3 M/QALY gained if the virus emerged after 25 years.DiscussionAt current prices, PRT is unlikely to be cost‐effective when judged against thresholds for medicines and treatments. Given significant additional willingness‐to‐pay for blood safety, PRT is only likely to be cost‐effective if a novel virus that causes chronic infection with significant morbidity and mortality emerges very soon after the introduction of PRT.
Active Commuting in Brazil: A Systematic Review and Meta-Analysis of Proportions
Authors: Santos Lucas P. , Azevedo Rafael A. , Ribeiro Indyanara C. , Santos Jhonnatan , Iraha Amanda , Roschel Hamilton , Gualano Bruno 
Published: December 2024

Background: Active commuting benefits both individual and planetary health. Estimating commuting behavior is desirable, although very challenging in large and regionally relevant nations like Brazil. Methods: This review (CRD42023431054) included observational studies that estimated prevalence of active commuting in Brazil for adults (≥18 y). We searched terms related to physical activity, commuting, prevalence estimates, and Brazilian geographical regions in 5 databases (PubMed, EMBASE, LILACS, CINAHL, and SPORTDiscus). For the quantitative synthesis, 2 categories were used based on the strictness of case definition: “high-volume threshold” (HIGH), considering “active” individuals with ≥150 minutes per week; and “low-volume threshold” (LOW), considering “active” individuals with ≥10 minutes per week of active commuting or self-reporting this behavior. Results: There were 37 studies included in the main model, totaling 52 individual prevalence estimates and 1,266,862 units. Prevalence estimates were: 17.4% (15.1%–19.9%) for HIGH and 44.2% (36.9%–51.5%) for LOW. Subgroup analysis revealed a prevalence of 20.5% (16.7%–24.9%) for men and 13.8% (10.2%–17.9%) for women using HIGH, and 43.4% (27.2%–60.4%) for men and 47.6% (32.1%–63.4%) for women using LOW categories. Most studies had high risk of bias. Conclusions: We herein provided a panorama of active commuting in Brazil. Standardized active commuting definitions and objective measures of commuting activity are lacking. Studies specific to some regions of Brazil were few or inexistent. Considering the global importance of Brazil, sheltering ecologically relevant biomes, we encourage new, high-quality studies assessing commuting and its potential impacts on individual and planetary health.
Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with
Schistosoma mansoni
infection: open-label, randomized, head-to-head, non-inferiority trial
Authors: Obonyo Charles O. , Were Vincent O. , Wamae Peter , Muok Erick M. O. 
Published: December 2024

ABSTRACT

Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating
Schistosoma mansoni
infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9–15 years) with
S. mansoni
infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled. Participants were randomly assigned (1:1:1:1:1) via a computer-generated block randomization procedure to receive a single oral dose of praziquantel (PZQ) (40 mg/kg/day) alone or in combination with a 3-day course (4 mg/kg of artesunate) of artesunate plus sulfalene-pyrimethamine (As + SP), artesunate plus amodiaquine (As + AQ), artesunate plus mefloquine (As + MQ) or dihydroartemisinin-piperaquine (DHAP). Laboratory technicians were masked to treatment allocation, but participants, clinicians, and study nurses were not. The primary outcomes were the cure rate and frequency of adverse events, which were assessed 6 weeks after treatment in the available case population using a per-protocol analysis. The non-inferiority margin was set at −10% for the risk difference in cure rates between combination therapy and PZQ alone. Between 12 September 2018 and 11 January 2019, 540 participants were assigned to receive PZQ alone (
n
= 108), PZQ plus As + SP (
n
= 108), PZQ plus As + AQ (
n
= 108), PZQ plus As + MQ (
n
= 108), or PZQ plus DHAP (
n
= 108). Primary outcome data were available for 523 (96.9%) participants. The cure rate was 82.5% (85/103) in PZQ alone, 81.7% (85/104) in PZQ plus As + SP, 76.2% (80/105) in PZQ plus As + AQ, 88.7% (94/106) in PZQ plus As + MQ, and 85.7% (90/105) in PZQ plus DHAP arm. Non-inferiority was declared for PZQ plus As + MQ (difference 6.2 [95% confidence interval: −3.3 to 15.6]) and PZQ plus DHAP (3.2 [−6.7 to 13.1]) but not for PZQ plus As + SP (−0.8 [−11.2 to 9.6]) or PZQ plus As + AQ (−6.3 [−17.3 to 4.6]). Adverse events were reported by 26% (138/540) of participants, including abdominal pain, headache, and vomiting. There were no serious adverse events. Alternatives to praziquantel should include praziquantel plus artesunate-mefloquine or praziquantel plus dihydroartemisinin-piperaquine. However, further multicentre trials are needed in different epidemiological settings and population groups to confirm these findings.

CLINICAL TRIALS

This study is registered with the Pan-African Clinical Trials Registry under
PACTR202001919442161
.
In vitro
resensitization of multidrug-resistant clinical isolates of
Enterococcus faecium
and
E. faecalis
through phage-antibiotic synergy
Authors: Ghatbale Pooja , Sah Govind Prasad , Dunham Sage , Khong Ethan , Blanc Alisha , Monsibais Alisha , Garcia Andrew , Schooley Robert T. , Cobián Güemes Ana G. , Whiteson Katrine , Pride David T. 
Published: December 2024

ABSTRACT

Bacteriophages are an increasingly attractive option for the treatment of antibiotic-resistant infections, but their efficacy is difficult to discern due to the confounding effects of antibiotics. Phages are generally delivered in conjunction with antibiotics, and thus, when patients improve, it is unclear whether the phages, antibiotics, or both are responsible. This question is particularly relevant for enterococcus infections, as limited data suggest phages might restore antibiotic efficacy against resistant strains. Enterococci can develop high-level resistance to vancomycin, a primary treatment. We assessed clinical and laboratory isolates of
Enterococcus faecium
and
Enterococcus faecalis
to determine whether we could observe synergistic interactions between phages and antibiotics. We identified synergy between multiple phages and antibiotics including linezolid, ampicillin, and vancomycin. Notably, antibiotic susceptibility did not predict synergistic interactions with phages. Vancomycin-resistant isolates (
n
= 6) were eradicated by the vancomycin-phage combination as effectively as vancomycin-susceptible isolates (
n
= 2). Transcriptome analysis revealed significant gene expression changes under antibiotic-phage conditions, especially for linezolid and vancomycin, with upregulated genes involved in nucleotide and protein biosynthesis and downregulated stress response and prophage-related genes. While our results do not conclusively determine the mechanism of the observed synergistic interactions between antibiotics and phages, they do confirm and build upon previous research that observed these synergistic interactions. Our work highlights how using phages can restore the effectiveness of vancomycin against resistant isolates. This finding provides a promising, although unexpected, strategy for moving forward with phage treatments for vancomycin-resistant
Enterococcus
infections.
Complete genome sequence of lytic bacteriophage BAU.Micro_SLP-22 infecting avian
Salmonella
spp.
Authors: Kallol Md. Arefin , Khan Mohammad Ferdousur Rahman , Alam Jahangir , Rahman Md. Bahanur , Rahman Marzia 
Published: December 2024

ABSTRACT

A lytic bacteriophage, BAU.Micro_SLP-22, was isolated from drain water in search of bio-controlling agents against avian salmonellosis. The phage genome is comprised of 59,738 bp with 56.96% guanine–cytosine content, encoding 81 protein-coding genes containing no transfer RNAs, antibiotic resistance, virulence, temperate marker, and clustered regularly interspaced short palindromic repeat coding sequences.
Comparative analysis of the human microbiome from four different regions of China and machine learning-based geographical inference
Authors: Lei Yinlei , Li Min , Zhang Han , Deng Yu , Dong Xinyu , Chen Pengyu , Li Ye , Zhang Suhua , Li Chengtao , Wang Shouyu , Tao Ruiyang 
Published: December 2024

ABSTRACT

The human microbiome, the community of microorganisms that reside on and inside the human body, is critically important for health and disease. However, it is influenced by various factors and may vary among individuals residing in distinct geographic regions. In this study, 220 samples, consisting of sterile swabs from palmar skin and oral and nasal cavities were collected from Chinese Han individuals living in Shanghai, Chifeng, Kunming, and Urumqi, representing the geographic regions of east, northeast, southwest, and northwest China. The full-length 16S rRNA gene of the microbiota in each sample was sequenced using the PacBio single-molecule real-time sequencing platform, followed by clustering the sequences into operational taxonomic units (OTUs). The analysis revealed significant differences in microbial communities among the four regions.
Cutibacterium
was the most abundant bacterium in palmar samples from Shanghai and Kunming,
Psychrobacter
in Chifeng samples, and
Psychrobacillus
in Urumqi samples. Additionally,
Streptococcus
and
Staphylococcus
were the dominant bacteria in the oral and nasal cavities. Individuals from the four regions could be distinguished and predicted based on a model constructed using the random forest algorithm, with the predictive effect of palmar microbiota being better than that of oral and nasal cavities. The prediction accuracy using hypervariable regions (V3-V4 and V4-V5) was comparable with that of using the entire 16S rRNA. Overall, our study highlights the distinctiveness of the human microbiome in individuals living in these four regions. Furthermore, the microbiome can serve as a biomarker for geographic origin inference, which has immense application value in forensic science.

IMPORTANCE
Microbial communities in human hosts play a significant role in health and disease, varying in species, quantity, and composition due to factors such as gender, ethnicity, health status, lifestyle, and living environment. The characteristics of microbial composition at various body sites of individuals from different regions remain largely unexplored. This study utilized single-molecule real-time sequencing technology to detect the entire 16S rRNA gene of bacteria residing in the palmar skin, oral, and nasal cavities of Han individuals from four regions in China. The composition and structure of the bacteria at these three body sites were well characterized and found to differ regionally. The results elucidate the differences in bacterial communities colonizing these body sites across different regions and reveal the influence of geographical factors on human bacteria. These findings not only contribute to a deeper understanding of the diversity and geographical distribution of human bacteria but also enrich the microbiome data of the Asian population for further studies.
Simulating a travel-related origin of
Candida auris
in New York–New Jersey
Authors: Verma Rita R. , Kiegle Edward , Keyel Alexander C. , Chaturvedi Sudha , Chaturvedi Vishnu 
Published: December 2024

ABSTRACT

Candida auris
first appeared in the United States in 2013 in New York–New Jersey (NY-NJ) and led to an unprecedented outbreak since 2016. We hypothesized
C. auris
’ introduction to NY-NJ was not a random event but related to travel patterns between South Asia and NY-NJ. New York City is a US hub for international passengers, including those from South Asia. We tested the hypothesis by simulating introductions to NY-NJ with a Monte Carlo simulation based on travel from South Asia, proportion of US population in NY-NJ, proportion of hospitals in NY-NJ, and finally, proportion of all travelers entering the United States through NY-NJ. The
C. auris
outbreak occurred during increasing travel and trade, and South Asia travel routes predict the distribution of early
C. auris
cases in NY-NJ. The local mobility network within hospitals and extended stay healthcare facilities were also relevant in the spread of
C. auris
. Our observations and simulations link travel patterns to
C. auris
origin and spread and warrant further investigations for understanding the continued spread of the pathogen.

IMPORTANCE

Candida auris
is an emerging fungal pathogen, with resistance to several antifungal drugs. Serious
C. auris
infections affect hospitalized patients and residents of long-term care facilities, although the pathogen can also be present on a healthy individual’s skin. Many studies have shown international introductions of
C. auris
to the United States. Here, we present a simulation that supports the hypothesis that the earlier introductions of
C. auris
in the New York–New Jersey area are not random but related to travel networks.